# Avricore Health Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Avricore Health Inc.). ## Overview Avricore Health Inc. is a health technology company focused on pharmacy-based point-of-care testing and digital health workflow tools, centered on its HealthTab platform. The company operates from Vancouver, Canada and serves health-system and retail-pharmacy channels, with an emphasis on connecting patients, pharmacies, and clinical testing services. ## Products & services • HealthTab point-of-care testing platform • Pharmacy-based diagnostic workflow software • Patient result reporting and engagement tools • Health screening and testing network services - **Point-of-care testing platform** (55%) — HealthTab software and related tools used to support in-pharmacy testing workflows and results delivery. - **Digital health workflow software** (25%) — Software that connects pharmacies, patients, and clinical processes around testing and screening. - **Testing services enablement** (15%) — Services and integrations that help pharmacies offer health screening and testing programs. - **Other health technology services** (5%) — Ancillary services and commercialization support linked to the platform ecosystem. - HealthTab point-of-care testing platform - Pharmacy-based diagnostic workflow software - Patient result reporting and engagement tools - Health screening and testing network services ## Customers Avricore sells into pharmacies and health-care service providers that want to offer convenient testing and screening at the point of care. Its platform is also relevant to patients who receive testing through participating pharmacies, and to partners that need digital results delivery and workflow integration. The business model depends on adoption by pharmacy networks and the clinical organizations that support them. - **Retail pharmacies** (primary) — Pharmacies buy HealthTab to offer testing and screening services in-store and to manage results efficiently. - **Health-care partners** (primary) — Clinical and health-system partners use the platform to extend access and coordinate testing workflows. - **Patients** (secondary) — Patients use the service indirectly through participating pharmacies for convenient point-of-care testing. - **Commercial and public programs** (secondary) — Organizations procure access to improve testing reach, digital reporting, and service convenience. - Retail pharmacies offering on-site testing services - Health systems and clinical partners using pharmacy channels - Patients receiving screening and test results through pharmacies - Commercial partners integrating digital workflow and reporting - Public-health or employer programs seeking local testing access ## Geography The company is based in Vancouver, British Columbia, and its reporting indicates a Canadian operating base. The business is exposed to pharmacy and health-care adoption patterns in North America, while the HealthTab platform also appears suited to broader international expansion. Geography matters because pharmacy networks, health regulations, and reimbursement pathways differ by market and affect rollout speed. - Headquartered in Vancouver, British Columbia - Canadian base for operations and corporate functions - North American pharmacy and health-care market exposure - Platform can be adapted for international pharmacy networks - Market access depends on local health regulation and adoption ## Strategy Avricore’s strategy centers on scaling the HealthTab platform through pharmacy channels and expanding the number of testing and screening use cases it can support. The company also appears focused on financing and commercialization efforts that support broader rollout, including geographic expansion beyond its home market. This strategy is important because the business depends on network adoption, recurring platform usage, and partner integration rather than standalone product sales. - **Scale pharmacy adoption** (short-term) — More participating pharmacies increase platform utility and commercial reach. - **Expand into new markets** (medium-term) — International expansion diversifies demand and enlarges the addressable market. - **Broaden service use cases** (medium-term) — Additional screening and testing applications can lift utilization per site. - Expand HealthTab adoption through pharmacy networks - Broaden testing and screening use cases - Pursue geographic expansion, including the UK - Strengthen partner integrations and commercialization - Use financing to support rollout and platform growth ## Risks Avricore faces commercialization risk because its platform must gain adoption from pharmacies and health partners before scaling meaningfully. It also carries execution risk in expanding across jurisdictions with different regulatory, reimbursement, and operating requirements. As with other early-stage health technology businesses, funding access, partner concentration, and product-market fit remain important risks. - **Slow pharmacy adoption** [high] — The business depends on pharmacies implementing new testing workflows and services. - **Geographic expansion execution** [medium] — Entering new markets requires local regulatory, clinical, and commercial adaptation. - **Financing dependence** [high] — The company has used equity financing to support operations and expansion. - **Partner concentration** [medium] — A platform business can be exposed to a small number of channel or service partners. - Pharmacy adoption may be slower than expected - Regulatory and reimbursement differences can delay expansion - Dependence on a limited set of commercialization partners - Financing needs may constrain rollout speed - Health-tech adoption depends on workflow integration ## Accounting The most important accounting issue is likely revenue recognition for platform access, implementation, and service arrangements, which may be recognized at different times depending on contract terms. Financing transactions and share issuance can also affect reported results through equity accounting and dilution, while any capitalized development or intangible assets may require impairment assessment if commercialization lags. Because the company is still scaling, period-to-period comparability can be affected by uneven deployment timing and one-time financing or transaction items. - **Revenue recognition** — Affects reported revenue timing and comparability across periods - **Intangible asset impairment** — Could require write-downs of capitalized assets - **Equity financing and dilution** — Affects share count, capital structure, and per-share measures - Revenue recognition may vary by software and service contract terms - Implementation and setup fees may be recognized differently from recurring services - Equity financings affect share count and diluted per-share metrics - Capitalized development or intangibles may face impairment risk - Rollout timing can create quarter-to-quarter volatility --- *Last updated: 2026-09-28T11:57:45.383050+00:00*